customizable online tool to review progress against cancer over time – is to inform public policy discussions and other efforts to accelerate continuous innovation against cancer. The tool is now even easier to use due to an interactive user interface and enhanced data comparison capabilities in a total of 12 cancer types. The CII may be accessed at www.pacenetworkusa.com/continuousinnovation.php.
The new CII will be featured at WCC in a poster presentation entitled, "Assessing the Evidence Supporting New Cancer Treatments: Phase III and Beyond." A presentation of the poster will take place on Wednesday, November 2, between 10:30 a.m. and 11:00 a.m. CEST, in E-pod 2 at the Palais des Congrès. It will be conducted by Silvia Paddock, Ph.D., lead CII researcher at Rose Li and Associates, a U.S.-based research firm that developed the CII for PACE.
Advancing the value discussion in cancer care
"Cancer is a very complex disease and most progress against it has not resulted from major breakthroughs, but rather, from continuous innovation or step-by-step advances over time," said Scott Shortenhaus, Director, U.S. PACE, Policy and Advocacy at Lilly Oncology. "The PACE CII systematically gathers objective data to help us understand how progress against cancer is achieved and is therefore an essential tool to use alongside the new frameworks developed by oncology-related organizations and institutions to define the value of cancer treatments."
According to Mr. Shortenhaus, data provided by the CII will help inform when and how a new cancer treatment should be evaluated and, by increasing our understanding of the research gaps and unmet needs within each cancer, demonstrate how a new cancer therapy adds value to the current armament of available treatments.
"This historical perspective and the reality of progress in cancer care are currently missing from the value frameworks," said Mr. Shortenhaus. "Therefore, Lilly's PACE initiative felt it essential to create a user-friendly version of the CII so that as many individuals who influence the course of cancer progress – including researchers, policymakers, health policy experts and patient advocates – are able to use it on demand for a wide variety of analyses."
Advocacy community reaction to the new CII has been very positive to date. Following is a sampling of feedback:
"The CII consolidates a vast amount of information into an easy-to-interpret visual," said Lynn M. Matrisian, PhD, MBA, Chief Research Officer, Pancreatic Cancer Action Network. "We are excited about using it to better see where progress is being made against cancer and where we can make future advancements."
"The visuals of the CII are very helpful to get a quick overview of where we are in the fight against cancer," said Pam Traxel, Vice President, Alliance Development & Philanthropy, American Cancer Society Cancer Action Network.
Advancing our knowledge of cancer progress
The CII enables users to: visualize progress against cancer over time; gain a better understanding of the evolution of cancer treatment progress and value; and consider the potential impact of policy reforms that affect the speed of continuous innovation and patient access. The new version of the tool provides enhanced data comparison capabilities in a total of 12 tumor types: breast, colorectal, endometrial, gastrointestinal stromal, kidney, liver, lung, pancreatic, prostate, skin (melanoma), stomach, and testicular.
At the heart of the CII are thousands of pieces of evidence curated and coded by trained analysts from authoritative, published sources, such as clinical trial records and meta-analyses, observational studies and historical references. The tool, which provides a layered interface with a range of information, generates summary graphs from which a user can access supporting evidence and additional information.